使用部分暂时闲置自有资金及募集资金进行现金管理 的核查意见 关于深圳华大智造科技股份有限公司 上海证券交易所: 中信证券股份有限公司（以下简称"中信证券"或"保荐机构"）作为深 圳华大智造科技股份有限公司（以下简称"华大智造"或"公司"）首次公开 发行股票并在科创板上市的保荐机构，根据《证券发行上市保荐业务管理办法》 《上海证券交易所科创板股票上市规则》《上海证券交易所科创板上市公司自 律监管指引第 1 号——规范运作》等相关规定履行持续督导职责，对华大智造 使用部分暂时闲置自有资金及募集资金进行现金管理事项进行了审慎核查，具 体核查情况如下： 中信证券股份有限公司 一、现金管理概述 （一）现金管理的目的 为提高自有资金及募集资金的使用效率，在不影响公司募投项目建设实施、 募集资金使用计划和保证募集资金安全且不影响公司主营业务的正常发展并确 保公司经营资金需求的前提下，公司将合理使用部分暂时闲置自有资金及募集 资金进行现金管理，本着股东利益最大化的原则，提高自有资金及募集资金使 用效益、增加股东回报。 （二）投资额度 公司及子公司拟使用最高额不超过人民币 20 亿元（含本数）的暂时闲置自 有资金及最高额不超过 ...

非大綱造 関西 2024年度"提质增效重回报" 行动方案 半大智造 [9]C 深圳华大智造科技股份有限公司 01 目 录 CONTENTS | 01 | 深耕生命科技领域 | 02 | | --- | --- | --- | | | 持续提升市占率 | | | 02 | 坚持科技创新驱动 | 06 | | | 加快发展新质生产力 | | | 033 | 优化财务管理 | 11 | | | 提升盈利质量 | | | 04 | 坚持规范运作 | 13 | | | 促进公司良性发展 | | | 015 | 持续强化投资者沟通 | 15 | | | 积极传递公司内在价值 | | | 05 | 持续注重投资者回报 | 17 | | | 共享公司发展成果 | | | 07 | 完善长效激励机制 | । ਰੇ | | | 实现风险共担、利益共享 | | | 08 | 主动承担社会责任 | 20 | | | 绘制可持续发展蓝图 | | | 09 | 真他 | 20 | 公司简介 深圳华大智造科技股份有限公司 (以下简称"公司")专注于生命科学与生物技术领域,以 生命中心法则为基础聚焦"读、写、存"三大体系核心工具的底层技术研 ...

证券代码：688114 证券简称：华大智造 公告编号：2024-027 深圳华大智造科技股份有限公司 2023 年度募集资金存放与实际使用情况的专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据中国证券监督管理委员会(以下简称"证监会")发布的《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要求（2022 年修订）》《上海证券交易 所科创板上市公司自律监管规则适用指引第 1 号——规范运作》等相关规定，深圳华 大智造科技股份有限公司（以下简称"公司"或"本公司"）就 2023 年度募集资金存 放与实际使用情况作如下专项报告： 一、募集资金基本情况 (一) 实际募集资金情况 | 截至 月 | 2022 | 年 | 12 | 31 | 日募集资金账户余额 | 2,504,750,153.96 | | --- | --- | --- | --- | --- | --- | --- | | 减：本年度使用的募集资金总额 | | | | | | 412,437,675.68 | | 减：本年度节余募集资金永久 ...

证券代码：688114 证券简称：华大智造 公告编号：2024-026 深圳华大智造科技股份有限公司 关于未弥补亏损达实收股本总额三分之一的公告 1 二、 应对措施 未来，公司将继续着力于开发更高密度的测序载片、提高测序质量、降低测 序成本、进一步提高测序读长。围绕着测序仪的不同领域应用开发，包括科研、 医学、农业等领域。除了常规测序业务之外，通过上下游联动合作，拓展更多基 于测序技术的应用领域。寻求新的利润增长点，提高公司盈利能力。 在业务管理方面，持续加强渠道网络建设，巩固并提升技术人员的服务水平。 不断构建和完善公司生态圈，与更多行业伙伴开展更广泛、更深入的合作，从而 拓宽自身的业务范围，优化业务管理模式，不断提升市场占有率。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 深圳华大智造科技股份有限公司（以下简称"公司"）于 2024 年 4 月 24 日 召开第二届董事会第五次会议，审议通过了《关于未弥补亏损达到实收股本总额 三分之一的议案》。根据毕马威华振会计师事务所（特殊普通合伙）为公司出具 的标准无保留意见的 ...

证券代码：688114 证券简称：华大智造 公告编号：2024-021 深圳华大智造科技股份有限公司 关于公司 2024 年度对外担保额度预计的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ●被担保人包括青岛华大智造科技有限责任公司、青岛华大智造极创科技有 限公司、青岛华大智造普惠科技有限公司、武汉华大智造科技有限公司、MGI Americas Inc.、Complete Genomics, Inc.等公司合并报表范围内的全资子公司。 ●公司及子公司拟为子公司的金融机构授信等融资业务及与客户所签署销 售合同下的履约义务等提供总额不超过人民币 10,000 万元的担保额度。截至 2023 年 12 月 31 日，公司及子公司对外担保总额为 3,683 万元，全部为公司对公 司全资子公司及全资子公司之间提供的担保，公司无逾期及涉及诉讼的对外担保。 ●本次担保是否有反担保：否 ●本事项无需提交公司股东大会审议。 一、担保情况概述 为满足子公司业务发展和经营需要，公司拟在 2024 年度为公司子公司向业 务 ...

证券代码：688114 证券简称：华大智造 公告编号：2024-020 深圳华大智造科技股份有限公司 关于公司 2023 年度利润分配预案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ●深圳华大智造科技股份有限公司（以下简称"公司"）2023 年度不进行 利润分配，资本公积金不转增股本。 ●本年度不进行利润分配的简要原因说明 公司目前处于成长阶段，需投入大量资金用于研发投入、产能扩大等方面， 不断提升公司技术实力与核心竞争力。公司对于未来资金需求较大，公司 2023 年度归属于母公司的净利润为负且合并报表口径累计未分配利润为负，考虑公司 目前产品研发及市场推广等资金需求量大的实际情况，为保障公司长远发展，根 据相关法律法规以及《公司章程》等规定，经公司审慎研究讨论，拟定 2023 年 度不进行利润分配。 ●公司 2023 年年度利润分配预案已经公司第二届董事会第五次会议和第二 届监事会第五次会议审议通过，尚需提交 2023 年年度股东大会审议。 一、利润分配预案内容 经毕马威华振会计师事务所（特殊 ...

环境、社会及公司治理（ESG）报告 年度 深圳华大智造科技股份有限公司 董事长致辞 走进华大智造 可持续发展变革 生命科技引领者 核心工具缔造者 合规治理先行者 成长价值共享者 生命家园守卫者 展望2024年 附录 目录 董事长致辞 | 01 | 走进华大智造 | 02 | 可持续发展变革 | | --- | --- | --- | --- | | 03 | 公司简介 | 11 | 可持续发展管理 | | 05 | 发展历程 | 15 | 主要的ESG风险和机遇 | | 07 | 企业荣誉 | 22 | 衡量可持续发展的工具 | | 可持续发展变革 | c | | --- | --- | | - 1 - | | 可持续发展策略 23 03 生命科技引领者 扩大基因组学可及性 29 31 | 31 | 拓展多元应用场景 | | --- | --- | | 33 | 助力精准医疗提升 | 赋能行业生态建设 35 43 | 05 | 合规治理先行者 | 06 | 成长价值共享者 | 07 | 生命家园守卫者 | | --- | --- | --- | --- | --- | --- | | 71 | 加强信息安全保 ...

本人武丽波，作为深圳华大智造科技股份有限公司（以下简称"公司"）的 独立董事，2023 年度，本人严格按照《中华人民共和国公司法》（以下简称《公 司法》）、《中华人民共和国证券法》（以下简称《证券法》）《上市公司治理 准则》《上市公司独立董事管理办法》等法律法规、规范性文件，以及《公司章 程》和《独立董事工作制度》等公司内部制度的相关规定，忠实履行职责，在董 事日常工作及重要决策中尽职尽责，从公司整体利益出发，发挥了独立董事的应 有作用，维护了公司和全体股东特别是中小股东的合法权益。 本人因任期届满，于 2023 年 9 月 20 日公司召开 2023 年第二次临时股东大 会选举产生新任独立董事后正式离任，不再担任公司董事会独立董事及各专门委 员会中相关职务。现将本人 2023 年度履行独立董事职责工作情况汇报如下： 一、独立董事的基本情况 （一） 公司董事会基本构成 报告期内，公司董事会由 12 名董事组成，其中独立董事 4 人，占董事会人 数三分之一，符合相关法律法规及公司制度的规定。 深圳华大智造科技股份有限公司 2023 年度独立董事述职报告 （二） 个人工作履历、专业背景以及兼职情况 本人武丽波，女 ...

Financial Performance - The company's revenue for Q1 2024 was ¥530,735,953.60, representing a decrease of 14.26% compared to the same period last year[4] - The net profit attributable to shareholders was a loss of ¥200,985,602.32, with a significant increase in losses compared to the previous year[4] - Total operating revenue for Q1 2024 was approximately ¥530.74 million, a decrease from ¥619.00 million in Q1 2023, representing a decline of about 14.3%[21] - The net loss for Q1 2024 was approximately ¥202.27 million, compared to a net loss of ¥150.05 million in Q1 2023, indicating an increase in losses of about 34.8%[22] - The total comprehensive loss for Q1 2024 was approximately ¥190.57 million, compared to a loss of ¥170.22 million in Q1 2023, reflecting an increase in comprehensive losses of about 11.9%[22] Cash Flow and Liquidity - The net cash flow from operating activities was negative at ¥218,660,254.19, indicating a decline in cash generation capabilities[4] - Cash flow from operating activities for Q1 2024 showed a net outflow of approximately ¥218.66 million, compared to a net outflow of ¥451.67 million in Q1 2023, indicating an improvement of about 51.6%[23] - The net cash flow from investing activities was -$167.33 million, compared to -$58.56 million in the previous period, indicating a significant increase in cash outflow for investments[24] - The total cash outflow from financing activities was $164.91 million, up from $19.56 million, reflecting a substantial rise in cash used for financing[24] - The ending balance of cash and cash equivalents decreased to $4.22 billion from $5.91 billion, showing a decline in liquidity[24] Assets and Liabilities - Total assets decreased by 4.91% to ¥10,038,331,079.32 compared to the end of the previous year[5] - Current assets decreased to ¥6,452,424,978.75 as of March 31, 2024, down 7.8% from ¥6,998,089,701.66 at the end of 2023[17] - Total liabilities decreased to ¥1,699,964,751.19, down 9.7% from ¥1,882,841,410.63[19] - Non-current assets increased slightly to ¥3,585,906,100.57, up from ¥3,558,997,459.97[18] - The company’s retained earnings showed a significant decline, with an unallocated profit of -¥662,422,660.38 compared to -¥461,437,058.06 in the previous year[19] Research and Development - Research and development (R&D) expenses totaled ¥202,456,558.64, accounting for 38.15% of revenue, an increase of 2.8 percentage points year-on-year[5] - Research and development expenses for Q1 2024 were approximately ¥202.46 million, a slight decrease from ¥218.80 million in Q1 2023, down by about 7.4%[21] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 6,832[9] - The largest shareholder, Shenzhen BGI Technology Holdings Group Co., Ltd., held 36.81% of the shares[9] Business Strategy and Market Position - The company plans to enhance its marketing network and market expansion efforts, which has led to increased sales expenses[8] - The company maintains a steady growth trend in its core business despite challenging macroeconomic conditions[15] - The company emphasizes its industry-leading position and technological advantages to ensure stable growth in its main business[15] - The report highlights the company's resilience and risk resistance capabilities in its main business after returning to normal operations[15] Product Development and Innovation - The gene sequencing instrument segment achieved revenue of RMB 449.44 million, representing a year-on-year growth of 4%[15] - Overseas revenue for the gene sequencing instrument segment reached RMB 157.11 million, with a year-on-year increase of 19%[15] - The company launched the new generation sequencing reagent StandardMPS 2.0, aiming to enhance sequencing accuracy from Q30 to Q40, significantly reducing sequencing costs[16] - In April 2024, the company introduced the MGISEQ-2000RS FluoXpert multi-omics analyzer, the first of its kind in China with integrated pathology and sequencing capabilities[16] - The MGIDS-1000 enzyme-directed evolution screening system was launched, featuring high-throughput microfluidic droplet screening capabilities[16] - The company plans to introduce the new sequencing reagent across all mainstream sequencing platforms in the second half of 2024[16] Accounting and Reporting Changes - The company has adopted new accounting standards starting in 2024, which may impact future financial reporting[25]

Financial Performance - The company reported a net profit attributable to the parent company of negative RMB 83,404,440.16 as of December 31, 2023, leading to a decision not to distribute profits for the year [5]. - The company has not achieved profitability since its listing, indicating ongoing challenges in financial performance [3]. - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB, representing a 25% year-over-year growth [12]. - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB for the fiscal year 2023, representing a 25% year-over-year growth [16]. - The company’s operating revenue for 2023 was approximately ¥2.91 billion, a decrease of 31.19% compared to ¥4.23 billion in 2022 [22]. - The net profit attributable to shareholders for 2023 was approximately -¥607.5 million, representing a 129.98% decrease from ¥2.03 billion in 2022 [22]. - The cash flow from operating activities for 2023 was approximately -¥870.1 million, a decline of 161.22% compared to ¥1.42 billion in 2022 [22]. - The basic earnings per share for 2023 was -¥1.46, down 127.76% from ¥5.26 in 2022 [23]. - The company reported a quarterly operating revenue of ¥619 million in Q1 2023, with a net profit of -¥149.8 million [26]. - The company’s main business revenue for 2023 was CNY 286,717.83 million, a year-on-year decrease of 31.85% [181]. - The company reported a revenue of CNY 291,122.23 million, a decrease of 31.19% year-on-year [177]. - The net profit after deducting non-recurring gains and losses was CNY -68,283.07 million, a decrease of 358.54% year-on-year [177]. Research and Development - The company is investing in R&D for new technologies, with a budget allocation of 150 million RMB for the upcoming year [12]. - Investment in R&D increased by 15%, totaling 150 million RMB, focusing on innovative technologies and product development [16]. - The company increased its R&D investment as a percentage of operating revenue to 31.26% in 2023, up from 19.25% in 2022, reflecting a 12.01 percentage point increase [24]. - The company achieved a total R&D investment of approximately ¥909.98 million, representing an increase of 11.74% compared to the previous year [135]. - R&D investment accounted for 31.26% of total revenue, an increase of 12.01 percentage points from the previous year [135]. - The company applied for 461 new patents and software copyrights during the reporting period, with a total of 1,945 applications to date [134]. - The company received 283 patents and software copyrights, bringing the total to 1,062 valid patents and copyrights [134]. - The company has developed multiple core technologies in gene sequencing, including DNBSEQ sequencing technology and automated sample processing technology [128]. Market Expansion and Strategy - The company provided a positive outlook for the next fiscal year, projecting a revenue growth of 30% [12]. - Market expansion plans include entering three new international markets, aiming for a 15% market share in each by the end of the next fiscal year [12]. - The company is considering strategic acquisitions to enhance its product portfolio, with a target of acquiring two companies within the next 18 months [12]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by 2025 [16]. - The company aims to enhance its brand visibility and product accessibility through various promotional activities and collaborations with key ecosystem partners [47]. - The company is actively expanding its market presence and product offerings in the life sciences and biotechnology sectors [65]. - The company has established a global partnership ecosystem to maximize commercial potential, collaborating with major research institutions and clinical enterprises for advanced technology applications [154]. Operational Efficiency and Risk Management - The company has outlined various operational risks in its management discussion, emphasizing the importance of risk management strategies [3]. - The company is implementing new strategies to improve operational efficiency, aiming for a 5% reduction in costs by the end of 2024 [16]. - The company plans to enhance its marketing network and optimize inventory management to mitigate risks [171]. - The company is closely monitoring international macroeconomic changes to manage foreign exchange risks effectively [172]. - The company has implemented measures to manage accounts receivable risks, but potential delays in collections could lead to significant bad debt losses [170]. Compliance and Governance - The audit report issued by KPMG Huazhen confirmed the financial statements are free from material misstatements, providing assurance on the accuracy of the financial reporting [4]. - There are no non-operational fund occupations by controlling shareholders or related parties, ensuring financial integrity [7]. - The company has not reported any violations of decision-making procedures regarding external guarantees, maintaining compliance with regulations [7]. - The company is committed to compliance with GDPR regulations, ensuring data protection and privacy for its users [15]. - The company emphasizes data privacy and security, adhering to GDPR and local regulations, ensuring the legality and transparency of data management processes [62]. Product Development and Innovation - The company launched the ultra-high throughput sequencer DNBSEQ-T20×2 and received regulatory approval for the DNBSEQ-G99, enhancing its product offerings in the clinical-grade sequencing market [31]. - The company launched the DCS Lab multi-omics frontier laboratory program, aiming to establish 10 labs globally to enhance research efficiency in genomics, cellomics, and spatiotemporal omics [53]. - The company launched the MGISP-NEX fully automated nucleic acid extraction and purification instrument, capable of processing liquid volumes from 50μL to 5000μL, enhancing efficiency and reducing manual operations in various research fields [39]. - The company launched the MGISP-NEX product during the reporting period, which integrates magnetic rod and liquid transfer technology for fully automated nucleic acid extraction from complex samples [82]. - The company has developed nucleic acid extraction technologies for various biological samples, achieving international leading levels with the launch of MGIEasy extraction kits [141]. - The company launched the upgraded MGISP-Smart 8 product, which has been successfully implemented by multiple partners [46]. Challenges and Risks - The company faced a significant decline in demand for laboratory automation products due to social environmental factors, leading to a decrease in revenue and a net profit loss during the reporting period [159]. - The company faces risks related to product upgrades and technology updates, which require significant R&D investment and may lead to low ROI if new products do not meet market expectations [160]. - Core talent loss and technology leakage pose significant risks, as the company relies on skilled personnel for R&D, and losing them could delay projects and diminish competitive advantages [161]. - The company has faced patent and trademark infringement lawsuits from competitors, which may limit its market expansion in affected regions like France and Turkey [162]. - The global life sciences market is increasingly competitive, with major players like Illumina and Thermo Fisher dominating the gene sequencing market, which poses challenges for the company in gaining market share [163].